Omega-3 Index Testing — Diagnostics & Biomarker Testing

Overview

The Omega-3 Index measures EPA (eicosapentaenoic acid) + DHA (docosahexaenoic acid) as a percentage of total fatty acids in red blood cell membranes, reflecting 3-4 months of omega-3 intake. It was developed by Dr. William Harris and represents the most accurate, stable biomarker of long-term omega-3 status — superior to plasma or serum measurements that reflect recent intake rather than tissue incorporation. The REDUCE-IT trial (n=8,179) demonstrated that icosapentaenoic acid (EPA) at 4 g/day in high-risk patients reduced major cardiovascular events by 25%. A 2021 meta-analysis found that each 1% increase in Omega-3 Index is associated with 9% reduction in coronary heart disease risk. Target range is 8-12%. The average American has an Omega-3 Index of 4-5% — the 'red zone.' Most commercial fish oil supplements raise the index by 1-2% over 3-4 months at standard doses; higher doses needed for deficient individuals.

Indications

• Omega-3 status monitoring and supplementation optimization
• Cardiovascular risk assessment (Omega-3 Index < 4% = high risk)
• Anti-inflammatory intervention tracking
• Cognitive health and neuroprotection monitoring
• Arrhythmia risk reduction assessment

Mechanism of Action

EPA and DHA are incorporated into red blood cell and cell membrane phospholipids, replacing pro-inflammatory omega-6 fatty acids (arachidonic acid) and changing the biophysical properties of all cell membranes throughout the body

Dosing

Evidence Grade

GRADE C

Safety & Contraindications

• Test alone is completely safe (finger stick or venipuncture)
• Results guide supplementation optimization — excessive omega-3 supplementation (> 3-4 g/day) increases bleeding risk
• Very high omega-3 intake may slightly increase LDL-C in some individuals